Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia
Phase of Trial: Phase III
Latest Information Update: 23 Feb 2017
At a glance
- Drugs Simvastatin; Telmisartan
- Indications Hypercholesterolaemia; Hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
- 23 Jan 2008 The expected completion date for this trial is now 1 Aug 2007.